	US 11,898,199 B2
	Detection of colorectal cancer and/or advanced adenomas
Marko Bitenc, Ljubljana (SI); Kristi Kruusmaa, Ljubljana (SI); Juan Martinez-Barea, Seville (ES); Christian Hense, Seville (ES); Marko Chersicola, Ljubljana (SI); and Primoz Knap, Ljubljana (SI)
Assigned to Universal Diagnostics, S.A., Seville (ES)
Filed by Universal Diagnostics, S.A., Seville (ES)
Filed on Nov. 11, 2019, as Appl. No. 16/680,427.
Prior Publication US 2021/0139948 A1, May 13, 2021
Int. Cl. C12Q 1/686 (2018.01)

CPC C12Q 1/686 (2013.01) [C12Q 2600/154 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01); G01N 2800/7028 (2013.01)]

11 Claims

1. A method of detecting hypermethylation of differentially methylated regions (DMRs), the method comprising:

detecting a methylation status of at least one methylation site within each of three or more differentially methylated regions (DMRs) of cell-free DNA from blood or plasma of a human subject suspected of having colorectal cancer and/or advanced adenoma, wherein the three or more DMRs comprise SEQ ID NO: 192, SEQ ID NO: 201, and SEQ ID NO: 210,

wherein detecting the methylation status comprises determining whether at least one methylation site within each of the three or more DMRs is hypermethylated.